Results 21 to 30 of about 1,029,181 (225)

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics [PDF]

Frontiers in Psychiatry
Graphical ...
Cristiano Chaves, Rafael G. dos Santos, Rafael G. dos Santos, Serdar M. Dursun, Serdar M. Dursun, Massimo Tusconi, Mauro Giovanni Carta, Elisa Brietzke, Jaime E. C. Hallak, Jaime E. C. Hallak, Jaime E. C. Hallak   +10 more
doaj   +2 more sources

Inhaled N, N-dimethyltryptamine diminishes connectivity between the ventral tegmental area and the nucleus accumbens: relevance to pathologies of mesolimbic and mesocortical pathways [PDF]

Scientific Reports
Reward processing is a broad psychological construct that can be parsed into distinct components known as “reinforcement learning” (learning), “reward responsiveness” (liking), and “motivation to obtain a reward” (wanting).
Gisela Lima, Carla Soares, Marta Teixeira, Marta Pais, Célia Cabral, Patrícia Rijo, Miguel Castelo-Branco   +6 more
doaj   +2 more sources

Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants. [PDF]

Neuropsychopharmacology
N,N-dimethyltryptamine (DMT) is a serotonergic psychedelic that is known for its short-lasting effects when administered intravenously. Several studies have investigated the administration of intravenous boluses or combinations of a bolus and a ...
Erne L, Vogt SB, Müller L, Nuraj A, Becker A, Klaiber A, Zuparic M, Varghese N, Eckert A, Rudin D, Luethi D, Liechti ME.   +11 more
europepmc   +2 more sources

Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N‐dimethyltryptamine – Implications for dose considerations [PDF]

Clinical and Translational Science, 2022
N,N‐dimethyltryptamine (DMT) is a psychedelic compound that is believed to have potential as a therapeutic option in several psychiatric disorders. The number of clinical investigations with DMT is increasing.
Emma Eckernäs, Christopher Timmermann, Robin Carhart‐Harris, Daniel Röshammar, Michael Ashton   +4 more
doaj   +2 more sources

Optimized infusion rates for N,N‐dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework [PDF]

CPT: Pharmacometrics & Systems Pharmacology, 2023
N,N‐dimethyltryptamine (DMT) is a psychedelic compound that is being studied as a therapeutic option in various psychiatric disorders. Due to its short half‐life, continuous infusion of DMT has been proposed to extend the psychedelic experience and ...
Emma Eckernäs, Jeroen Koomen, Christopher Timmermann, Robin Carhart‐Harris, Daniel Röshammar, Michael Ashton   +5 more
doaj   +2 more sources

<i>N</i>,<i>N</i>-dimethyltryptamine mitigates experimental stroke by stabilizing the blood-brain barrier and reducing neuroinflammation. [PDF]

Sci Adv
N,N-dimethyltryptamine (DMT) is a psychoactive molecule present in the human brain. DMT is under clinical evaluation as a neuroprotective agent in poststroke recovery. Yet, its mechanism of action remains poorly understood.
László MJ, Vigh JP, Kocsis AE, Porkoláb G, Hoyk Z, Polgár T, Walter FR, Szabó A, Djurovic S, Merkely B, Alpár A, Frecska E, Nagy Z, Deli MA, Nardai S.   +14 more
europepmc   +2 more sources

Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-<i>N,N</i>-dimethyltryptamine in Mice. [PDF]

ACS Pharmacol Transl Sci, 2023
Analogues of 4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin) are being sold on recreational drug markets and developed as potential medications for psychedelic-assisted therapies.
Glatfelter GC, Naeem M, Pham DNK, Golen JA, Chadeayne AR, Manke DR, Baumann MH.   +6 more
europepmc   +2 more sources

The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action. [PDF]

Addict Biol
Alcohol use disorder (AUD) remains one of the most prevalent psychiatric disorders worldwide with high economic costs. Current treatment options show modest efficacy and relapse rates are high.
Tap SC.
europepmc   +2 more sources

Safety, Pharmacokinetics, and Pharmacodynamics of a 6‐h N,N‐Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double‐Blind, Placebo‐Controlled Trial [PDF]

Clinical and Translational Science
The serotonergic psychedelic N,N‐dimethyltryptamine (DMT) presumably stimulates neuroplasticity in vitro and in vivo, by which it may exert neuroprotective effects during acute ischemic stroke.
Katelijne V. van derHeijden, Rob G. J. A. Zuiker, Marije E. Otto, Christopher S. Bryan, Nancy Stewart, Christopher Stillwell, Marieke L. De Kam, Marloes B. vanLeuken, Joop M. A. vanGerven, Gabriel E. Jacobs   +9 more
doaj   +2 more sources

Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence [PDF]

Frontiers in Psychiatry, 2022
BackgroundThe psychedelic 5-MeO-DMT has shown clinical potential due to its short duration and ability to induce mystical experiences. However, a phenomenon known as “reactivations” (similar to “flashbacks”) is a poorly understood and frequently reported
Ana María Ortiz Bernal, Charles L. Raison, Rafael L. Lancelotta, Alan K. Davis, Alan K. Davis   +4 more
doaj   +2 more sources